Results 201 to 210 of about 68,267 (269)
Impact of prophylaxis, inhibitors, and genetics on joint outcomes according to the IPSG-MRI score in hemophilia A, B and vWD type 3. [PDF]
Seeliger A +7 more
europepmc +1 more source
Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use. [PDF]
Hassan E +6 more
europepmc +1 more source
Balancing Promise and Peril: Hemophilia Gene Therapy Insights. [PDF]
Akula S +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pediatrics In Review, 1991
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire +2 more sources
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire +2 more sources

